Related Experiment Videos
Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina
Anastasia A Katinioti1, Dimitris Tousoulis, Emanuel Economou
1Cardiology Unit, Hippokration Hospital, Athens University Medical School, S. Karagiorga 69, 16675, Athens, Greece.
Insights
Basic fibroblast growth factor (bFGF) is elevated in coronary artery disease patients. Percutaneous coronary intervention (PTCA) significantly reduced bFGF levels, which remained stable for six months post-procedure.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
Background:
- Basic fibroblast growth factor (bFGF) plays a role in coronary atherosclerosis and angiogenesis.
- Elevated bFGF levels are observed in patients with coronary artery disease.
Purpose of the Study:
- To assess changes in serum bFGF levels before, immediately after, and six months after percutaneous coronary angioplasty (PTCA).
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma bFGF.
- Measurements were taken in 28 PTCA patients, 20 coronary artery disease patients undergoing angiography, and 28 healthy controls.
Main Results:
- Pre-procedure bFGF levels were significantly higher in both patient groups compared to healthy controls.
- Following PTCA, bFGF levels decreased significantly at 24 hours, 3 months, and 6 months.
- bFGF levels in the PTCA group were 3.2±0.6, 1.7±0.3, and 2.7±0.6 pg/ml at these time points, respectively.
Conclusions:
- bFGF levels are elevated in patients with coronary artery disease.
- PTCA leads to a significant reduction in bFGF levels.
- bFGF levels remain stable for at least six months post-PTCA, suggesting a response to the intervention.
Abstract:
Basic fibroblast growth factor (bFGF) has been implicated in the pathogenesis of coronary atherosclerosis and in angiogenesis. We assessed the changes in serum bFGF before, immediately after, and 6 months after coronary angioplasty (PTCA). Using the ELISA methods we measured plasma bFGF in 28 patients who underwent PTCA, in 20 patients with coronary artery disease who underwent elective coronary angiography and in 28 healthy subjects. Before PTCA and coronary angiography, bFGF plasma levels were similar in both patient groups (4.4+/-1.0 vs. 3.3+/-0.5 pg/ml), but were significantly higher compared with those of the control group (0.8+/-0.1 pg/ml, P<0.05). By 24 h, 3 months and 6 months after PTCA, bFGF levels had decreased significantly in the PTCA group (3.2+/-0.6, 1.7+/-0.3 and 2.7+/-0.6 pg/ml, respectively, P<0.05). In conclusion, these findings show that bFGF levels are elevated in patients with coronary artery disease. Following PTCA, bFGF levels decreased significantly and remained stable for 6 months after the procedure. Thus, bFGF level may change in response to PTCA in patients with coronary artery disease and stable angina.